Liraglutide is a long-acting synthetic analog of glucagon-like peptide-1 (GLP-1), an incretin hormone that regulates blood sugar and appetite.
It works by binding to GLP-1 receptors, stimulating insulin secretion, reducing glucagon release, slowing gastric emptying, and promoting satiety.
Liraglutide is FDA-approved for the treatment of type 2 diabetes (as Victoza®) and chronic weight management (as Saxenda®).
Beyond these approved indications, it is studied in research for cardiovascular protection, fatty liver disease, and neurodegenerative disorders.
All other applications remain experimental.
How The Peptide Is Used in Research Settings
- Studied for weight management and obesity through appetite suppression and reduced caloric intake.
- Investigated in type 2 diabetes for glycemic control and insulin sensitivity improvement.
- Explored in cardiovascular research for reducing atherosclerosis and inflammation.
- Examined in neurodegenerative disease models for potential neuroprotective effects.
- Studied in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) research.
Proposed Uses (Research Areas)
- Obesity and weight management studies.
- Type 2 diabetes and insulin resistance models.
- Cardiovascular health research.
- Liver health studies (NAFLD/NASH).
- Neuroprotection and cognitive health research.
How It Is Dosed in Research Settings
- Injectable (Subcutaneous): Research dosing often begins at 0.6 mg daily and titrates up to 1.2–1.8 mg for diabetes studies, and up to 3 mg daily for weight management studies.
- Cycle length: Clinical research commonly extends 16–56 weeks to measure long-term effects on weight, metabolism, and cardiovascular health.
- Handling: Supplied in pre-formulated pens or vials for injection; requires refrigeration for stability.
Important Considerations
- Regulatory status: FDA-approved for type 2 diabetes and obesity; all other uses are experimental.
- Evidence base: Large-scale clinical trials support its role in glycemic control, weight reduction, and cardiovascular risk reduction. Ongoing research is evaluating additional benefits.
- Safety: Common side effects include nausea, vomiting, diarrhea, and decreased appetite. Rare risks include pancreatitis, gallbladder disease, and thyroid C-cell tumors in animal models.
Disclaimer
This material is provided for educational purposes only and summarizes published research on Liraglutide.
It is not medical advice. Except for its narrow FDA-approved uses, Liraglutide is experimental and should not be viewed as a therapy for medical use.
This peptide is for research use only.